Columbia Plunges Following Adcomm Meeting on Prochieve
By Mari Serebrov
Monday, January 23, 2012
Columbia Laboratories Inc. fought a losing battle Friday in a statistical throwdown with the FDA at an advisory committee meeting convened to consider whether data from the PREGNANT trial are enough to support a preterm birth indication for Columbia's Prochieve (progesterone gel 8 percent).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.